Terms ending in 2039
Every in-force patent on Biogen Ma Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,474,113 | Methods of Treating Spinal Muscular Atrophy In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 11,753,461 | Optimized Factor VIII Genes In force · High confidence | Bioverativ Therapeutics Inc. | In force | High confidence | |
| US 10,899,753 | Inhibiting Agents for Bruton's Tyrosine Kinase In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 11,459,324 | O-GLYCOPROTEIN-2-Acetamido-2-Deoxy-3-D-GLYCOPYRANOSIDASE Inhibitors In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 12,404,263 | ASK1 Inhibiting Agents In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 11,697,670 | Methods for Purifying Antibodies Having Reduced High Molecular Weight Aggregates In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 12,275,728 | O-GLYCOPROTEIN-2-Acetamido-2-Deoxy-3-D-GLUCOPYRANOSIDASE Inhibitors In force · High confidence | Biogen Ma Inc. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
6 of these are in force and held by Biogen Ma Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.